AUG 14, 2026 · PHASE 1 TRIAL
A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease
ClinicalTrials.gov
This is a Phase 1 trial registration with no posted results; it is an early-stage safety and tolerability study in a small estimated cohort designed to establish feasibility and dose range.
Reported
Estimated enrollment50
Study phasePHASE1
Primary outcome measure 1Frequency of Adverse Events, Up to 32 months